

Ref: 59/SE/LC/2025-26

Date: November 12, 2025

Scrip Code BSE: 544122
NSE: ENTERO
ISIN: INE010601016

To,
**Head, Listing Compliance
Department
BSE Limited**
Phiroze Jeejeebhoy Towers Dalal
Street,
Mumbai - 400 001.

**Head, Listing Compliance Department
National Stock Exchange of India Limited**
Exchange Plaza, Plot No. C/1. G Block,
Bandra -Kurla Complex, Bandra (East),
Mumbai- 400051

Dear Sir/Madam,

Subject: Outcome of Board Meeting held on November 12,2025.

Reference: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. ("SEBI Listing Regulations")

Pursuant to Regulation 30 of the SEBI Listing Regulations, we wish to inform you that the Board of Directors of the Company, at its meeting held today, inter alia, considered and approved of the following:

1. The execution of definitive agreements for acquiring 80 % stake in Bioaide Technologies Private Limited directly.
2. The Board has approved, inter-alia, entering into a binding Memorandum of Understanding for acquiring 51% stake in Anand Chemiceutics Private Limited, subject to satisfactory completion of due diligence and execution of the definitive agreements.

The details required to be furnished in compliance with Regulation 30 read with Part A of Schedule III of SEBI Listing Regulations and SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11 November 2024, as amended, are enclosed as **Annexure-1** and **Annexure 2** respectively.

The Board Meeting commenced at 03:30 PM (IST) and concluded at 06:00 PM (IST).

This is for your information and records.

Yours faithfully,
For **Entero Healthcare Solutions Limited**

Sanu Kapoor
**Vice President- General Counsel, Company Secretary
& Compliance Officer**

Details in terms of Regulation 30 read with Para A of Part A of Schedule III of SEBI Listing Regulations and SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11 November 2024:

Sr. No.	Particulars	Details
1	Name of the target entity, details in brief such as size, turnover etc.	<p>M/s. Bioaide Technologies Private Limited, a company incorporated in Delhi, India, bearing CIN U51397DL1996PTC081135 (“Bioaide”/ “Target Company”).</p> <p>Bioaide is inter -alia engaged in the business of Wholesale of distribution of medical devices and other healthcare and allied products.</p> <p>Paid-up equity share capital of Bioaide is INR. 9,50,400/- (Indian Rupees Nine Lakhs Fifty Thousand and Four Hundred only) consisting of 95,040 equity shares having face value of INR 10/- each (Ten Only)</p> <p>The turnover of Bioaide is mentioned in Annexure 1</p>
2	whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm s length”	No, the acquisition shall not fall within related party transaction and promoter/promoter group/ group companies do not have any interest in the Bioaide.
3	Industry to which the entity being acquired belongs	Bioaide operates in same industry i.e. Wholesale distribution of medical devices and other healthcare and allied products.
4	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	The business of Bioaide is in line with the business of the Company i.e. wholesale distribution of medical devices and other allied products.
5	brief details of any governmental or regulatory approvals required for the acquisition;	Not applicable.
6	indicative time period for completion of the acquisition;	The acquisition shall be completed by February 15, 2026.
7	consideration whether cash consideration or share swap or any other form and details of the same	The acquisition of Bioaide will be through cash consideration.
8	cost of acquisition and/ or the price at which the shares are acquired;	The cost of acquisition shall range between INR 31.13 Crore to INR 36 Crore for acquiring 80% (eighty percent) stake in the target company subject to adjustments for net

		debt, normalized working capital and achievement of certain conditions.
9	percentage of shareholding / control acquired and / or number of shares acquired;	80% of Shareholding
10	brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	Bioaide is inter-alia engaged in the business of wholesale distribution of medical devices and other allied products. Bioaide was incorporated on August 13, 1996. Bioaide conducts its business only in India. The turnover of Bioaide is mentioned in Annexure 1 .

Annexure 1

Details of revenue are mentioned below:

(Figures in Rs. Mn.)

Name of the Company	F.Y - 2024-2025 (Audited)	F.Y - 2023-2024 (Audited)	F.Y - 2022-2023 (Audited)
Bioaide	557.82	529.08	475.42

Details in terms of Regulation 30 read with Para A of Part A of Schedule III of SEBI Listing Regulations and SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11 November 2024:

Sr. No.	Particulars	Details
1	Name of the target entity, details in brief such as size, turnover etc.	<p>Anand Chemiceutics Private Limited, a company incorporated in Pune, India, bearing CIN U51909PN2022PTC214898 (“Anand Chemiceutics”/ “Target Company”).</p> <p>Anand Chemiceutics is inter-alia engaged in the business of Wholesale distribution of medical devices with its allied products and turnkey projects in healthcare institutions.</p> <p>Paid-up equity share capital of Anand Chemiceutics is INR. 10,00,000/- (Indian Rupees Ten Lakhs only) consisting of 1,00,000 equity shares having face value of INR 10/- each (Ten Only)</p> <p>The turnover of Anand Chemiceutics is mentioned in Annexure 1</p>
2	whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm s length”	No, the acquisition shall not fall within related party transaction and promoter/promoter group/ group companies do not have any interest in the Anand Chemiceutics.
3	Industry to which the entity being acquired belongs	Anand Chemiceutics operates in same industry i.e. Wholesale distribution of medical devices and other healthcare and allied products.
4	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	The business of Anand Chemiceutics is in line with the business of the Company i.e. wholesale distribution of medical devices and other allied products.
5	brief details of any governmental or regulatory approvals required for the acquisition;	Not applicable.
6	indicative time period for completion of the acquisition;	The acquisition shall be completed in the financial year 25-26.
7	consideration whether cash consideration or share swap or any other form and details of the same	The acquisition of Anand Chemiceutics will be through cash consideration.
8	cost of acquisition and/ or the price at which the shares are acquired;	The cost of acquisition shall range between INR 210 Crore to INR 230 Crore for acquiring 51% (Fifty one percent) stake in the target company subject to adjustments for net debt,

		normalized working capital and achievement of certain conditions.
9	percentage of shareholding / control acquired and / or number of shares acquired;	Anand Chemiceutics Pvt. Ltd. shall acquire the business from Anand Chemiceutics and Anand Healthcare Services via slump sale basis and the Company shall acquire 51% Stake in Anand Chemiceutics Pvt. Ltd.
10	brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	<p>Anand Chemiceutics is inter-alia engaged in the business of wholesale distribution of medical devices and other allied products.</p> <p>Anand Chemiceutics was incorporated on September 20, 2022. Anand Chemiceutics conducts its business only in India.</p> <p>The turnover of Anand Chemiceutics, Anand Healthcare Services and Anand Chemiceutics Private Limited is mentioned in Annexure 1.</p>

Annexure 1

Details of revenue are mentioned below:

(Figures in Rs. Mn.)

Name of the Company	F.Y - 2024-2025 (Un-audited)	F.Y - 2023-2024 (Audited)	F.Y - 2022-2023 (Audited)
Anand Chemiceutics	2,876	2,149	1,663
Anand Healthcare Services	1,723	992	672
Anand Chemiceutics Private Limited	150	-	-
Total	4,749	3,142	2,335